Published in Radiology on March 01, 2010
Quantitative measurement of N-acetyl-aspartyl-glutamate at 3 T using TE-averaged PRESS spectroscopy and regularized lineshape deconvolution. Magn Reson Med (2011) 1.02
Soft constraints in nonlinear spectral fitting with regularized lineshape deconvolution. Magn Reson Med (2012) 0.83
Regional and tissue-specific differences in brain glutamate concentration measured by in vivo single voxel MRS. J Neurosci Methods (2014) 0.83
Smoothness of in vivo spectral baseline determined by mean-square error. Magn Reson Med (2013) 0.78
Proton MR spectroscopy of lesion evolution in multiple sclerosis: Steady-state metabolism and its relationship to conventional imaging. Hum Brain Mapp (2017) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Multiple sclerosis. N Engl J Med (2000) 12.69
Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed (2001) 6.56
Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med (1998) 3.16
Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med (2000) 3.13
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
Cortical lesions in multiple sclerosis. Brain (1999) 2.83
1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging (2004) 2.47
Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson (1999) 2.42
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed (2001) 2.29
1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology (2006) 2.26
Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain (2005) 2.17
Changes in the structural complexity of the aged brain. Aging Cell (2007) 1.96
The effects of normal aging on myelin and nerve fibers: a review. J Neurocytol (2003) 1.95
A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci (1979) 1.73
Effect of windowing and zero-filled reconstruction of MRI data on spatial resolution and acquisition strategy. J Magn Reson Imaging (2001) 1.69
Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. Magn Reson Imaging (1998) 1.63
Natural history of multiple sclerosis. Ann Neurol (1994) 1.48
Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol (2003) 1.41
Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging (2005) 1.36
Optimizing the efficiency of high-field multivoxel spectroscopic imaging by multiplexing in space and time. Magn Reson Med (2006) 1.35
MRI in multiple sclerosis: what's inside the toolbox? Neurotherapeutics (2007) 1.34
T2 measurement and quantification of glutamate in human brain in vivo. Magn Reson Med (2006) 1.29
SNR versus resolution in 3D 1H MRS of the human brain at high magnetic fields. Magn Reson Med (2001) 1.29
Human brain-structure resolved T(2) relaxation times of proton metabolites at 3 Tesla. Magn Reson Med (2007) 1.28
Optimizing the precision-per-unit-time of quantitative MR metrics: examples for T1, T2, and DTI. Magn Reson Med (2007) 1.22
Toward quantitative short-echo-time in vivo proton MR spectroscopy without water suppression. Magn Reson Med (2006) 1.13
Age dependence of regional proton metabolites T2 relaxation times in the human brain at 3 T. Magn Reson Med (2008) 1.13
Chemical-shift artifact reduction in Hadamard-encoded MR spectroscopic imaging at high (3T and 7T) magnetic fields. Magn Reson Med (2007) 1.10
MRI techniques to monitor MS evolution: the present and the future. Neurology (2002) 1.08
Fast mapping of the T2 relaxation time of cerebral metabolites using proton echo-planar spectroscopic imaging (PEPSI). Magn Reson Med (2007) 1.08
MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry (2009) 1.07
Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol Sci (2001) 1.04
Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology (2007) 1.04
Reducing voxel bleed in Hadamard-encoded MRI and MRS. Magn Reson Med (2006) 1.00
The optimal MR acquisition strategy for exponential decay constants estimation. Magn Reson Imaging (2008) 1.00
High field MR imaging and 1H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol (2007) 0.95
T2 relaxation time analysis in patients with multiple sclerosis: correlation with magnetization transfer ratio. Eur Radiol (2003) 0.94
Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J Neurol Sci (2005) 0.94
Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain (1999) 0.92
Short echo time proton magnetic resonance spectroscopic imaging of macromolecule and metabolite signal intensities in the human brain. Magn Reson Med (1996) 0.91
Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience. Radiology (2004) 0.88
Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis. Neurol Res (2006) 0.81
Retrospective correction for T1-weighting bias in T2 values obtained with various spectroscopic spin-echo acquisition schemes. Magn Reson Imaging (2009) 0.77
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol (2003) 4.44
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol (2004) 3.56
Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. AJNR Am J Neuroradiol (2002) 2.94
Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2008) 2.83
Diffuse axonal injury in mild traumatic brain injury: a diffusion tensor imaging study. J Neurosurg (2005) 2.78
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology (2008) 2.34
Myocardial T1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson (2011) 2.30
Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2013) 2.29
Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. Radiology (2006) 2.22
Finite element analysis applied to 3-T MR imaging of proximal femur microarchitecture: lower bone strength in patients with fragility fractures compared with control subjects. Radiology (2014) 2.15
Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol (2007) 2.02
Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative analysis. AJNR Am J Neuroradiol (2002) 2.02
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging (2010) 1.96
Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology (2009) 1.94
T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson (2012) 1.88
Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology (2013) 1.86
Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic. Pediatrics (2008) 1.85
T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology (2012) 1.83
Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT. Radiology (2005) 1.78
Cardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm (2013) 1.73
Small pulmonary nodules: volume measurement at chest CT--phantom study. Radiology (2003) 1.73
Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology (2004) 1.72
Age-related non-Gaussian diffusion patterns in the prefrontal brain. J Magn Reson Imaging (2008) 1.72
Free-breathing radial 3D fat-suppressed T1-weighted gradient echo sequence: a viable alternative for contrast-enhanced liver imaging in patients unable to suspend respiration. Invest Radiol (2011) 1.72
Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging. J Magn Reson Imaging (2010) 1.70
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Short-term DTI predictors of cognitive dysfunction in mild traumatic brain injury. Brain Inj (2008) 1.68
Kidney function: glomerular filtration rate measurement with MR renography in patients with cirrhosis. Radiology (2011) 1.66
Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology (2012) 1.62
Left ventricular global function index by magnetic resonance imaging--a novel marker for assessment of cardiac performance for the prediction of cardiovascular events: the multi-ethnic study of atherosclerosis. Hypertension (2013) 1.61
Myocardial T1 mapping with MRI: comparison of look-locker and MOLLI sequences. J Magn Reson Imaging (2011) 1.59
Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol (2003) 1.59
Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol (2012) 1.58
Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. AJNR Am J Neuroradiol (2005) 1.56
Thalamus and cognitive impairment in mild traumatic brain injury: a diffusional kurtosis imaging study. J Neurotrauma (2011) 1.56
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson (2012) 1.55
Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery (2006) 1.54
Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med (2005) 1.50
Free-breathing contrast-enhanced multiphase MRI of the liver using a combination of compressed sensing, parallel imaging, and golden-angle radial sampling. Invest Radiol (2013) 1.49
Zwilch, a new component of the ZW10/ROD complex required for kinetochore functions. Mol Biol Cell (2003) 1.48
Sex-specific normalized reference values of heart and great vessel dimensions in cardiac CT angiography. AJR Am J Roentgenol (2011) 1.43
Multi-detector row CT attenuation measurements: assessment of intra- and interscanner variability with an anthropomorphic body CT phantom. Radiology (2007) 1.40
Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing post-prostatectomy hernia. BJU Int (2012) 1.39
Characterizing brain oxygen metabolism in patients with multiple sclerosis with T2-relaxation-under-spin-tagging MRI. J Cereb Blood Flow Metab (2012) 1.36
Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet C Semin Med Genet (2003) 1.36
Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI. AJR Am J Roentgenol (2013) 1.35
Optimizing the efficiency of high-field multivoxel spectroscopic imaging by multiplexing in space and time. Magn Reson Med (2006) 1.35
Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging (2011) 1.34
Cochlear implantation in prelingually deafened adolescents. Arch Pediatr Adolesc Med (2012) 1.34
Age-related total gray matter and white matter changes in normal adult brain. Part II: quantitative magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol (2002) 1.33
Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol (2007) 1.32
The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.32
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res (2009) 1.31
Human brain-structure resolved T(2) relaxation times of proton metabolites at 3 Tesla. Magn Reson Med (2007) 1.28
Myocardial infarction: optimization of inversion times at delayed contrast-enhanced MR imaging. Radiology (2004) 1.27
Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology (2012) 1.27
Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol (2005) 1.27
3D nongadolinium-enhanced ECG-gated MRA of the distal lower extremities: preliminary clinical experience. J Magn Reson Imaging (2008) 1.27
Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. J Magn Reson Imaging (2009) 1.27
Assessment of thalamic perfusion in patients with mild traumatic brain injury by true FISP arterial spin labelling MR imaging at 3T. Brain Inj (2009) 1.27
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol (2004) 1.23
Anterior cingulate cortex γ-aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch Gen Psychiatry (2011) 1.23
Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol (2009) 1.23
Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res (2004) 1.22
Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med (2003) 1.22
Comparison of the effectiveness of saturation pulses in the heart at 3T. Magn Reson Med (2008) 1.22
Optimizing the precision-per-unit-time of quantitative MR metrics: examples for T1, T2, and DTI. Magn Reson Med (2007) 1.22
Intravoxel incoherent motion and diffusion-tensor imaging in renal tissue under hydration and furosemide flow challenges. Radiology (2012) 1.21
Human hippocampal subfields in young adults at 7.0 T: feasibility of imaging. Radiology (2010) 1.20
Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology (2008) 1.20
Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage (2006) 1.19
Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. AJR Am J Roentgenol (2010) 1.18
White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J Neurol Sci (2009) 1.18
Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab (2007) 1.16